Loading…
Reported covered position: Intern, Rep. Paris (84); LA, Rep. Paris (85-86)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Preserving Access to Life-Saving Medications Act of 2011
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
Issues relating to global drug safety; H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; STAAR Act relating to antimicrobial surveillance; H.R. 2245 & S. 296 - Preserving Access to Life-Saving Medications Act; S. 1882 - Fair Generics Act
Preserving Access to Life-Saving Medications Act of 2011
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MIRACA LIFE SCIENCES via BROWN RUDNICK LLP
2012 · second_quarter · Q2
Education on issues related to "in-office ancillary" exemption to "Stark Law"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOSPIRA, INC. via BROWN RUDNICK LLP
2012 · second_quarter · Q2
Source: Senate LDA
H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; H.R. 2245 & S. 296 - Preserving Access to Life-Saving Medications Act; STAAR Act relating to antimicrobial surveillance; H.R. 4332 - Generic Drug Application Review Fairness Act of 2012; H.R. 5651 & S.2516 & S.3187 - FDA Safety and Innovation Act; P.L. 111-14 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 2295 - Patient Safety and Generic Labeling Improvement Act
Safeguarding America's Pharmaceuticals Act of 2011
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
Issues relating to global drug safety; H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; STAAR Act relating to antimicrobial surveillance; H.R. 2245 & S. 296 - Preserving Access to Life-Saving Medications Act; S. 1882 - Fair Generics Act
Safeguarding America's Pharmaceuticals Act of 2011
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; H.R. 2245 & S. 296 - Preserving Access to Life-Saving Medications Act; STAAR Act relating to antimicrobial surveillance; H.R. 4332 - Generic Drug Application Review Fairness Act of 2012; H.R. 5651 & S.2516 & S.3187 - FDA Safety and Innovation Act; P.L. 111-14 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 2295 - Patient Safety and Generic Labeling Improvement Act
Generic Drug Application Review Fairness Act of 2012
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
Issues relating to REMS and Orange Book patent listing S. 1882 - Fair GeneRxics Act H.R. 4332 - Generic Drug Appliction Review Fairness Act of 2012 H.R. 5651 & S. 2516 & S. 3187 - FDA Safety and Innovation Act
Generic Drug Application Review Fairness Act of 2012
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; H.R. 2245 & S. 296 - Preserving Access to Life-Saving Medications Act; STAAR Act relating to antimicrobial surveillance; H.R. 4332 - Generic Drug Application Review Fairness Act of 2012; H.R. 5651 & S.2516 & S.3187 - FDA Safety and Innovation Act; P.L. 111-14 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 2295 - Patient Safety and Generic Labeling Improvement Act
Food and Drug Administration Reform Act of 2012
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
Issues relating to REMS and Orange Book patent listing S. 1882 - Fair GeneRxics Act H.R. 4332 - Generic Drug Appliction Review Fairness Act of 2012 H.R. 5651 & S. 2516 & S. 3187 - FDA Safety and Innovation Act
Food and Drug Administration Reform Act of 2012
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; H.R. 2245 & S. 296 - Preserving Access to Life-Saving Medications Act; STAAR Act relating to antimicrobial surveillance; H.R. 4332 - Generic Drug Application Review Fairness Act of 2012; H.R. 5651 & S.2516 & S.3187 - FDA Safety and Innovation Act; P.L. 111-14 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 2295 - Patient Safety and Generic Labeling Improvement Act
H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; H.R. 2245 & S. 296 - Preserving Access to Life-Saving Medications Act; STAAR Act relating to antimicrobial surveillance; H.R. 4332 - Generic Drug Application Review Fairness Act of 2012; H.R. 5651 & S.2516 & S.3187 - FDA Safety and Innovation Act; P.L. 111-14 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 2295 - Patient Safety and Generic Labeling Improvement Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2012 · second_quarter · Q2
Issues relating to REMS and Orange Book patent listing S. 1882 - Fair GeneRxics Act H.R. 4332 - Generic Drug Appliction Review Fairness Act of 2012 H.R. 5651 & S. 2516 & S. 3187 - FDA Safety and Innovation Act
Filing targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
UNITED CONCORDIA COMPANIES, INC. via BROWN RUDNICK LLP
2012 · second_quarter · RR
Dental Benefits Programs
MIRACA LIFE SCIENCES via BROWN RUDNICK LLP
2012 · second_quarter · RR
Closing physician self-referred loophole related to anatomic pathology testing
HOSPIRA, INC. via BROWN RUDNICK LLP
2012 · first_quarter · Q1
Issues relating to global drug safety; H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; STAAR Act relating to antimicrobial surveillance; H.R. 2245 & S. 296 - Preserving Access to Life-Saving Medications Act; S. 1882 - Fair Generics Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2012 · first_quarter · Q1
Issues relating to generic drug user fees, global drug safety, REMS and Orange Book listing S. 1882 - Fair Generics Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE